Microbix mobilizes SWATT team to help companies worldwide expand flu vaccine production
Microbix Biosystems Inc. is establishing a Special Workgroup for Applied technology transfer (SWATT) that shall be instrumental in helping manufacturers significantly boost the amount of flu vaccine produced throughout the world.
The SWATT team will be sent to facilities adopting the Microbix proprietary virus yield enhancement technology - VIRUSMAX(TM). The team is expected to be operational this Fall. It will spend several weeks in each location helping customers implement the technology and training local personnel.
At present, only about 350 million doses of flu vaccine are produced annually in the world. There are only three countries that produce enough vaccine domestically to immunize their populations - Canada, France, and Australia. Every other country lacks the manufacturing capacity to meet its own needs. The largest domestic deficits are the U.S., China and India.
According to the company, Microbix' technology has been proven to double vaccine production output. It was also announced that Australia has indicated that it will issue a patent on this technology to Microbix. Similar patent protection has already been allowed in the U.S., Canada and India, and a number of other applications in major markets are currently pending.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Gene Bridges Announces Distribution Agreement with CAMBIO for Red/ET Recombination Kits
Modeling NAFLD with human pluripotent stem cell derived immature hepatocyte like cells
Agilent Thought Leader Award Presented to Renowned Drug Discovery Researcher Professor - Award to Chinese Scientist Supports the Use of Various Molecular Approaches to Cancer Research
Vitamins doing gymnastics: Scientists capture first full image of vitamin B12 in action - Work by University of Michigan and MIT team yields new understanding of crucial reaction in the body and in CO2-scrubbing bacteria
Positive Results in Proof-of-Concept Study with Sustained Release Treatment for Uveitis
Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan - Abbott will retain its branded generics pharmaceuticals business in emerging markets
Stanford researchers explore link between human birth defect syndrome, cancer metastasis
Asia-Pacific continues to drive global healthcare investment, innovation and growth ASEAN - A US$150 billion healthcare market by 2017, says Frost & Sullivan
Pharmacogenomics study finds rare gene variants critical for personalized drug treatment
